Brad Robling
Directeur/Membre du Conseil chez Auron Therapeutics, Inc.
Profil
Brad Robling is currently a Director at Auron Therapeutics, Inc. He previously worked as a Director-Investor Relations at Eli Lilly & Co.
Postes actifs de Brad Robling
| Sociétés | Poste | Début |
|---|---|---|
Auron Therapeutics, Inc.
 Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Brad Robling
| Sociétés | Poste | Fin |
|---|---|---|
| ELI LILLY AND COMPANY | Public Communications Contact | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Entreprise privées | 1 |
|---|---|
Auron Therapeutics, Inc.
Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Commercial Services |